Oxyargin (Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate)

Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate, the active ingredient in Oxyargin, is an opioid analgesic presented as an oral tablet for oral use. It treats moderate to severe pain in adult patients and helps reduce opioid‑induced constipation. GNH USA supplies Oxyargin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxyargin combines an opioid agonist with a peripheral antagonist to manage pain while limiting constipation. It is indicated for: - Chronic severe pain: provides effective analgesia while mitigating opioid‑induced constipation. - Cancer‑related pain: manages moderate to severe pain in oncology patients. - Opioid‑induced constipation: naloxone component reduces constipation without compromising analgesia.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel motility. - Dizziness: transient light‑headedness. - Somnolence: increased sleepiness. - Headache: mild cranial discomfort. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that may be life‑threatening. - Severe hypotension: marked drop in blood pressure. - Opioid dependence or withdrawal: signs of addiction or abrupt cessation symptoms. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Adrenal insufficiency: fatigue, weakness, low blood pressure. - Severe gastrointestinal obstruction: abdominal pain and vomiting.

Before prescribing Oxyargin, clinicians should consider several safety measures. - Pain assessment: confirm severity and need for opioid therapy. - Respiratory monitoring: watch for signs of depression, especially in opioid‑naïve patients. - Hepatic/renal function: adjust use if liver or kidney impairment is present. - Gastrointestinal obstruction: avoid in patients with known blockage or severe constipation. - Elderly patients: start at lower doses and monitor closely for sedation. - Store at ambient temperature: keep in the original pack, protect from moisture.

Oxyargin may interact with other medicines, requiring careful review. Major Interactions (Avoid): - CNS depressants (benzodiazepines, barbiturates, alcohol): risk of profound sedation and respiratory depression. - Strong CYP3A4 inhibitors (ketoconazole, erythromycin): increase oxycodone plasma levels. - Monoamine oxidase inhibitors (MAOIs): potential for serotonin syndrome. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampin, carbamazepine): may reduce analgesic effect. - Diuretics: can exacerbate hypotension. - Antihistamines and antidepressants (SSRIs): may increase sedation or serotonin-related effects.